KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $4.3 billion.

  • Gsk's Cash & Current Investments fell 373.23% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year decrease of 373.23%. This contributed to the annual value of $4.7 billion for FY2024, which is 2646.16% down from last year.
  • Latest data reveals that Gsk reported Cash & Current Investments of $4.3 billion as of Q3 2025, which was down 373.23% from $5.1 billion recorded in Q2 2025.
  • Gsk's 5-year Cash & Current Investments high stood at $14.7 billion for Q1 2022, and its period low was $3.5 billion during Q1 2024.
  • Its 5-year average for Cash & Current Investments is $5.7 billion, with a median of $5.0 billion in 2021.
  • In the last 5 years, Gsk's Cash & Current Investments skyrocketed by 11341.64% in 2022 and then crashed by 7504.88% in 2023.
  • Gsk's Cash & Current Investments (Quarter) stood at $5.8 billion in 2021, then soared by 59.0% to $9.2 billion in 2022, then plummeted by 30.36% to $6.4 billion in 2023, then decreased by 26.0% to $4.7 billion in 2024, then dropped by 9.04% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q3 2025, $5.1 billion for Q2 2025, and $5.7 billion during Q1 2025.